At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 91 enrolled
Drug / intervention
80 mg ixekizumabdrug
Likely dose
80 mg ixekizumabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis
In Brief
A Phase 3 clinical trial evaluating 80 mg ixekizumab for Psoriasis. Completed, enrolled 91 participants across 17 sites.
Detailed Summary
This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionSep 2013
Study CompletionSep 2017
TodayJul 2026
First PostedJun 20, 2012
Enrollment StartJun 1, 2012
Primary CompletionSep 1, 2013
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.0 years ago
Interventions
80 mg ixekizumabdrug
Administered SC